Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about AstraZeneca present two new phase IIIb trials for Forxiga
AstraZeneca announced two new randomised, placebo-controlled Phase IIIb outcome trials with Forxiga (dapagliflozin), an SGLT-2 inhibitor currently indicated for the treatment of type-2 diabetes. These two large outcome trials will help to define the potential role of dapagliflozin in the management of chronic kidney disease and chronic heart failure respectively, in people with and without type-2 diabetes.
- Read more about Array BioPharma Announces Phase 3 BEACON CRC SPA Agreement with FDA
Array BioPharma announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) related to BEACON CRC, a global Phase 3 trial of encorafenib and Erbitux® (cetuximab), with or without binimetinib, versus standard of care in patients with BRAF-mutant colorectal cancer (CRC) who have previously received first-or second-line systemic therapy.
- Read more about Fluxion Biosciences launch IsoFlux Cytation Imager for automated CTC analysis
Fluxion Biosciences, Inc. announced that it has launched a new imaging system, the IsoFlux Cytation Imager, designed to work exclusively with the IsoFlux Liquid Biopsy System and CTC Enumeration Kit. The IsoFlux Cytation Imager comes pre-configured with all components and software required for automated CTC image acquisition.
- Read more about New Polymers can kill Superbugs
Tiny, star-shaped molecules are effective at killing bacteria that can no longer be killed by current antibiotics, new research shows.
- Read more about Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint
Merck announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. Both 5 mg and 15 mg daily doses of ertugliflozin showed significantly greater reductions in A1C* of 0.69 percent and 0.76 percent, respectively, compared with placebo (p<0.001, for both comparisons), when added to patients on a background of sitagliptin (100 mg/day) and stable metformin (≥1500 mg/day). These study results were presented for the first time during an oral session at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany.
- Read more about Synthetic nanoparticles can differentiate lung cancer cells from healthy cells
Researchers with the Harold C. Simmons Comprehensive Cancer Center successfully developed a synthetic polymer that can transport a drug into lung cancer cells without going inside of normal lung cells.

Since conventional chemo drugs indiscriminately kill all rapidly dividing cells to halt the growth of cancer, these selective nanoparticles could decrease side effects by reducing drug accumulation in normal cells.
- Read more about Pfizer Launches New “Moodivator” App
Pfizer Inc announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive episode in any given year.
- Read more about Medtronic get FDA Approval of First Drug-Coated Balloon for Treatment of ISR
Medtronic plc announced that the U.S. Food and Drug Administration (FDA) approved the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) as a treatment for in-stent restenosis (ISR) in patients with peripheral artery disease (PAD). This is the first DCB that has gained approval to treat ISR in the U.S. FDA approval was based on ISR data from the IN.PACT Global Study compared to a standard percutaneous balloon angioplasty (PTA) control.
- Read more about BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA
BioXcel, a privately held biopharmaceutical company based in Connecticut, announced that the U. S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BXCL101 for the treatment of Neurofibromatosis Type 2 (NF2), an orphan disease with significant unmet medical need. BXCL101 is the first and only systemic therapy being developed to eliminate existing lesions and prevent the formation of new lesions by targeting the molecular mechanism of NF2 pathophysiology.
- Read more about Akari Therapeutic’s Coversin receive Orphan Drug Designation from the U.S. FDA
Akari Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted to Akari an Orphan Drug Designation for recombinant protein inhibitor of complement factor 5 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Coversin, Akari’s lead clinical product, which falls within the Orphan Drug Designation, is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC).

[adsense:336x280:8701650588]